As announced to the market on 9 and 26 November 2020, cervical cancer screening technology company, TruScreen Group Limited (NZX: TRU) (TruScreen or the Company) capital raising initiative, by way of a public offer, to raise up to NZD$2 million (“Offer”) in conjunction with TruScreen’s application for the dual listing of its shares on the Australian Securities Exchange (ASX), closes on 18 December 2020.
TruScreen is pleased to advise that acceptances have already achieved the planned raise of NZ$1.5m and the Board has resolved to accept further applications of up to NZ$500,000 as oversubscriptions, per the maximum raise of NZ$2 million as stated in the Product Disclosure Statement (PDS).
Applications can be made through the online application portal at https://www.truscreenshareoffer.co.nz/. A copy of the registered PDS in support of the Offer is available on the online application portal. Australian applications can be made at www.onmarket.com.au
An application has been made to the ASX for TruScreen to be admitted to the Official List of ASX as an ASX Foreign Exempt Listing and for quotation of the new shares to be offered in Australia on the ASX.
If TruScreen is admitted to the official list of ASX, then those Australian based investors in the Offer will initially have their Shares quoted on the ASX. Once dual listed, shareholders can select either the Australian or New Zealand sub-register to hold their shares to suit their investment needs.
The Offer is conditional upon the ASX approving the admission of TruScreen to the Official List of the ASX as an ASX Foreign Exempt Listing and for the quotation of the new shares issued to Australian investors on the ASX on or before that Closing Date (as that date may be varied from time to time). In the event that this condition is not satisfied, then the Offer will not proceed, and all application moneys received by the Company will be refunded to investors in full and without deduction within 5 business days.